Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

NCT02883049 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

5949

Enrollment

NIH

Sponsor class

Conditions

B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
Central Nervous System Leukemia
Testicular Leukemia

Interventions

DRUG: Clofarabine
DRUG: Cyclophosphamide
DRUG: Cytarabine
DRUG: Dasatinib
DRUG: Daunorubicin Hydrochloride
DRUG: Dexamethasone
DRUG: Doxorubicin Hydrochloride
DRUG: Etoposide
DRUG: Hydrocortisone Sodium Succinate
OTHER: Laboratory Biomarker Analysis
DRUG: Leucovorin Calcium
DRUG: Mercaptopurine
DRUG: Methotrexate
DRUG: Pegaspargase
DRUG: Prednisone
RADIATION: Radiation Therapy
DRUG: Thioguanine
DRUG: Vincristine Sulfate

Sponsor

National Cancer Institute (NCI)